<DOC>
	<DOCNO>NCT01163851</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics pharmacodynamics single dose PF-04950615 ( RN316 ) volunteer stable dos atorvastatin . PF-04950615 ( RN316 ) investigational drug currently study cholesterol lower therapy .</brief_summary>
	<brief_title>Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 ( RN316 ) In Combination With Atorvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>On stable dos atorvastatin ( 40 mg daily ) 45 day prior Day 1 . BMI 18.5 40 kg/m2 inclusive , body weight equal low 150 kg . History cardiovascular event ( e.g. , MI ) past year . Poorly control Type 1 Type 2 Diabetes mellitus ( definition : uncontrolled diabetes define HBIAc &gt; 9 % ) . Poorly control hypertension ( uncontrolled hypertension define systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg , even treatment ) . Subjects hypertension control stable dosage antihypertensive medication include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>